Effects of standard treatment on the dynamics of matrix metalloproteinases gene expression in patients with acute coronary syndromes

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 1108-1116

  Kułach, Andrzej ^a   Da̧bek, Józefa ^a   Głogowska Ligus, Joanna ^a   Garczorz, Wojciech ^a   Ga̧sior, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Acute coronary syndrome; Gene expression; Matrix metalloproteinases

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BISOPROLOL; CLOPIDOGREL; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MESSENGER RNA; METOPROLOL; QUINAPRIL; RAMIPRIL; SIMVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; ATHEROSCLEROSIS; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MONOCYTE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA EXTRACTION; UPREGULATION;

EID: 79551494126     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70373-X     Document Type: Article

References (27)

1. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L: AtheroGene Investigators: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation, 2003, 107, 1579-1585.
2. Chen F, Eriksson P, Hansson GK, Herzfeld I, Klein M, Hansson LO, Valen G: Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int J Mol Med, 2005, 15, 57-65.
3. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acidguanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162, 156-159.
4. Ebihara I, Nakamura T, Tmino Y, Shimada N, Koide H: Metalloproteinase 9 mRNA expression in monocytes from patients with chronic renal failure. Am J Nephrol, 1998, 18, 305-310.
5. Funayama H, Ishikawa SE, Kubo N, Katayama T, Yasu T, Saito M, Kawakami M: Increases in interleukin-6 and matrix metalloproteinase 9 in the infarct related coronary artery of acute myocardial infarction. Circ J, 2004, 68, 451-454.
6. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res, 2002, 90, 251-262.
7. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest, 1994, 94, 2493-2503.
8. Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW: Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells: effects of tumor necrosis factor α, interleukin 1 and phorbol ester. Biochem J, 1993, 296, 803-809.
9. Howard EW, Bullen EC, Banda MJ: Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. J Biol Chem, 1991, 266, 13070-13075.
10. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K: Plasma levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J, 2001, 141, 211-217.
11. Johnson JL, Baker AH, Oka K, Chan L, Newby AC, Jackson CL, George SJ: Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation, 2006, 113, 2435-2444.
12. Kaden JJ, Dempfle CE, Sueselbeck T, Brueckmann M, Poerner TC, Haghi D, Haase KK, Borggrefe M: Time-dependent changes in the plasma concentrations of matrix metalloproteinase 9 after acute myocardial infarction. Cardiology, 2003, 99, 140-144.
13. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T et al.: Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol, 1998, 32, 368-372.
14. Kalela A, Koivu TA, Höyhtyä M: Association of serum MMP-9 with autoantibodies against oxidized LDL. Atherosclerosis, 2002, 160, 161-165.
15. Katsuda S, Kaji T: Atherosclerosis and extracellular matrix. J Atheroscler Thromb, 2003, 10, 267-274.
16. Kazes I, Elalamy I, Sraer JD, Hatmi M, Nguyen G: Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood, 2000, 96, 3064-3069.
17. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation, 2002, 105, 1135-1143.
18. Nakaya R, Uzui H, Shimizu H, Nakano A, Mitsuke Y, Yamazaki T, Ueda T, Lee JD: Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. Int J Cardiol, 2005, 105, 67-73.
19. Papaspyridonos M, Smith A, Burnand KG, Taylor P, Padayachee S, Suckling KE, James CH et al.: Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler ThrombVasc Biol, 2006, 26, 1837-1844.
20. Robbesyn F, Augé N, Vindis C, Cantero AV, Barbaras R, Negre-Salvayre A, Salvayre R: High-density lipoproteins prevent the oxidized low-density lipoprotein-induced endothelial growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. Arterioscler Thromb Vasc Biol, 2005, 25, 1206-1212.
21. Schmoker JD, McPartland KJ, Fellinger EK, Boyum J, Trombley L, Ittleman FP, Terrien C 3rd et al.: Matrix metalloproteinase and tissue inhibitor expression in atherosclerotic and nonatherosclerotic thoracic aortic aneurysms. J Thorac Cardiovasc Surg, 2007, 133, 155-161.
22. Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, MacFadyen RJ: Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol, 2005, 96, 339-345.
23. Toy LW: Matrix metalloproteinases: their function in tissue repair. J Wound Care, 2005, 14, 20-22.
24. Vihinen P, Kahari VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer, 2002, 99, 157-166.
25. Vincenti MP: The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol Biol, 2001, 151, 121-148.
26. Vu TH, Werb Z: Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev, 2000, 14, 2123-2133.
27. Wibaut-Berlaimont V, Randi AM, Mandryko V, Lunnon MW, Haskard DO, Naoumova RP: Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis. J Thromb Haemost, 2005, 3, 677-685.